Exposures to silica dust, solvents or heavy metals increase the likelihood of developing various forms of myositis, ...

US biotech Abcuro has reeled in $200 million in third-round financing that should allow it to complete its pivotal trial of ...

The Boston-area company’s previous raises were also aimed at getting its investigational antibody treatment for inclusion ...

The funding will be used to complete the Phase II/III trial of ulviprubart, and to support commercial launch preparation.

Abcuro Inc. has raised a $200 million Series C financing to fund late-stage development and support commercial launch ...

Sanofi-backed Abcuro has secured $200 million in series C funds to power its anti-KLRG1 antibody through a phase 2/3 muscle ...

Samantha Ruth Prabhu shares valuable insights on the importance of mental and physical health in relationships following her ...

Frampton announced 10 spring concerts in January. He'd briefly considered farewell dates following his 2019 diagnosis with ...

The importance of independent funding for rare diseases like myositis cannot be overstated. Projects increase understanding and gather preliminary data to support applications for larger grants.” ...

Funding was led by New Enterprise Associates, with participation from Foresite Capital and multiple other investors.

State Theatre New Jersey will present Rock & Roll Hall of Fame inductee and Grammy Award-winning guitarist, Peter Frampton – ...

Polymyositis Market Opportunities . As polymyositis is an underserved rare disease, the ongoing development of emerging therapies like Dazukibart (PF-06823859) and Enpatoran (M5049) provides an ...